HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 26, Issue 2, Pages 207-231 (May 2006)


View previous. 7 of 17 View next.

Mechanisms of Allergen-Specific Immunotherapy: T-Regulatory Cells and More

Johan Verhagen, PhD, Kurt Blaser, PhD, Cezmi A. Akdis, MD, Mübeccel Akdis, MD, PhDCorresponding Author Informationemail address

Activation-induced cell death, anergy, or immune response modulation by regulatory T cells (Treg cells) are essential mechanisms of peripheral T-cell tolerance. Genetic predisposition and environmental instructions tune thresholds for the activation of T cells, other inflammatory cells, and resident tissue cells in allergic diseases. Skewing allergen-specific effector T cells to a Treg-cell phenotype seems to be crucial in maintaining a healthy immune response to allergens and successful allergen-specific immunotherapy. The Treg-cell response is characterized by an abolished allergen-specific T-cell proliferation and the suppressed secretion of T-helper 1– and T-helper 2–type cytokines. Suppressed proliferative and cytokine responses against allergens are induced by multiple suppressor factors, including cytokines such as interleukin-10 (IL-10) and transforming growth factor β (TGF-β), and cell surface molecules such as cytotoxic T-lymphocyte antigen-4, programmed death-1, and histamine receptor 2. The increased levels of IL-10 and TGF-β produced by Treg cells potently suppress IgE production while simultaneously increasing the production of noninflammatory isotypes IgG4 and IgA, respectively. In addition, Treg cells directly or indirectly suppress the activity of effector cells of allergic inflammation, such as mast cells, basophils, and eosinophils. In conclusion, peripheral tolerance to allergens is controlled by multiple active suppression mechanisms on T cells, regulation of antibody isotypes, and suppression of effector cells. The application of current knowledge of Treg cells and related mechanisms of peripheral tolerance may soon lead to more rational and safer approaches to the prevention and cure of allergic disease.

Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland

Corresponding Author InformationCorresponding author

 The authors' laboratories are supported by the Swiss National Foundation Grants: 32-105865, 32-100266, and Global Allergy and Asthma European Network (GA2LEN).

PII: S0889-8561(06)00022-1

doi:10.1016/j.iac.2006.02.008


View previous. 7 of 17 View next.